Brokerages expect Mylan NV (NASDAQ:MYL) to post sales of $3.25 billion for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Mylan’s earnings. The highest sales estimate is $3.28 billion and the lowest is $3.20 billion. Mylan posted sales of $3.08 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.5%. The business is scheduled to issue its next quarterly earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Mylan will report full-year sales of $11.56 billion for the current financial year, with estimates ranging from $11.50 billion to $11.59 billion. For the next financial year, analysts expect that the company will report sales of $11.99 billion, with estimates ranging from $11.82 billion to $12.17 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Mylan.
Mylan (NASDAQ:MYL) last posted its earnings results on Tuesday, November 5th. The company reported $1.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.03. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3.01 billion. During the same period in the prior year, the business posted $1.25 earnings per share. Mylan’s revenue for the quarter was up 3.5% on a year-over-year basis.
MYL traded up $0.04 on Friday, hitting $17.27. The company had a trading volume of 5,291,138 shares, compared to its average volume of 6,651,576. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.43 and a quick ratio of 0.84. Mylan has a 52-week low of $16.63 and a 52-week high of $35.07. The stock has a fifty day simple moving average of $18.53 and a 200-day simple moving average of $19.32. The firm has a market capitalization of $9.14 billion, a P/E ratio of 3.77, a P/E/G ratio of 0.95 and a beta of 1.75.
In other Mylan news, insider Goulds Bruce 8,000,000 shares of the business’s stock in a transaction that occurred on Friday, November 8th. Company insiders own 0.82% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Advisory Services Network LLC lifted its stake in shares of Mylan by 170.0% during the 2nd quarter. Advisory Services Network LLC now owns 1,520 shares of the company’s stock valued at $29,000 after buying an additional 957 shares in the last quarter. NuWave Investment Management LLC increased its holdings in Mylan by 1,111.0% in the 2nd quarter. NuWave Investment Management LLC now owns 2,192 shares of the company’s stock valued at $42,000 after acquiring an additional 2,011 shares during the last quarter. Rational Advisors LLC increased its holdings in Mylan by 1,111.0% in the 2nd quarter. Rational Advisors LLC now owns 2,192 shares of the company’s stock valued at $42,000 after acquiring an additional 2,011 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in Mylan by 92.9% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,367 shares of the company’s stock valued at $46,000 after acquiring an additional 1,140 shares during the last quarter. Finally, CSat Investment Advisory L.P. increased its holdings in Mylan by 258.9% in the 2nd quarter. CSat Investment Advisory L.P. now owns 2,835 shares of the company’s stock valued at $54,000 after acquiring an additional 2,045 shares during the last quarter. Institutional investors own 84.01% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More: How is the LIBOR rate calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.